

EVAXION

Evaxion raises nearly \$17 million in Q4

December 20, 2019

Copenhagen, Denmark, December 20, 2019 – Evaxion Biotech, a clinical stage company specializing in the development of AI-driven immunotherapies to improve lives of patients with cancer and infectious diseases, announces the closing of nearly \$17 million in funding, in the fourth quarter of 2019.

“This round of financing provides the company with the necessary funds to continue to advance the clinical work of the company’s EVX-01 personalized cancer immunotherapy in unresectable metastatic melanoma, non-small cell lung cancer (NSCLC) & bladder cancer, as well as prepare EVX-02, a Phase 1b/2, study of personalized adjuvant immunotherapy in melanoma subjects, who are at high risk for recurrence. Additionally, EVX-02 will evaluate a novel delivery technology for Evaxion ‘s neoepitope-targeted personalized immunotherapy and thus expand our ongoing efforts in a cancer with high unmet medical need,” says Lars Wegner, CEO.

About Evaxion

Evaxion Biotech is an AI-driven clinical stage immunotherapy company focused on discovering and developing novel drugs to treat cancer and infectious disease using immuno-informatics. The company leverages two unique and highly scalable AI platforms, with the potential to rapidly generate multiple unique immunotherapy programs. Its lead program EVX-01 is a personalized peptide immunotherapy, targeting neoepitopes in melanoma, non-small cell lung cancer (NSCLC) and bladder cancer. Topline data from a phase I trial with EVX-01 are expected in H1 2020.